Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 1 trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California. Show more
Location: 855 Oak Grove Avenue, Menlo Park, CA, 94025, United States | Website: https://orukatx.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
1.461B
52 Wk Range
$5.49 - $32.28
Previous Close
$30.21
Open
$30.07
Volume
697,844
Day Range
$29.38 - $31.08
Enterprise Value
1.117B
Cash
349.2M
Avg Qtr Burn
-22.42M
Insider Ownership
2.95%
Institutional Own.
95.20%
Qtr Updated
09/30/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|---|---|
ORKA-001 (IL-23p19 Antibody) Details Psoriasis | Phase 2b Initiation | |
ORKA-002 (IL-17A/F Antibody) Details Psoriasis | Phase 2 Initiation | |
ORKA-001 Details Psoriasis | Phase 2a Data readout | |
ORKA-002 Details Psoriasis | Phase 1 Data readout |
